On December 3, 2024, Bristol Myers Squibb announced a collaboration agreement with three-year-old startup AI Proteins.[1] According to its founder, Chris Bahl, PhD, AI Proteins uses “AI, synthetic biology, and laboratory automation to rapidly design and optimize novel miniproteins with ideal drug-like properties.”[2] The end goal of this collaboration is likely biologic products
The utilization of artificial intelligence (“AI”) is becoming ubiquitous across a wide range of industry sectors. The biotech industry is no exception.
AI-driven platforms have become increasingly useful to biotech innovators in many areas including in discovering and developing drugs. For example, a 2022 article by McKinsey & Company estimated that nearly 270 companies have
Critical and Emerging Technologies (CET) are of vital importance to the U.S. government. Therefore, it has made CET funding and support a top priority.
The U.S. National Security Strategy identifies expanding economic prosperity and opportunity as one of three primary goals.
The following critical and emerging technology areas are deemed of critical importance to U.S.
We recently spoke with Satish Grampurohit, Co-founder and CEO, Cogniquest Technologies, Bengaluru, India. Cogniquest is a provider of an AI-enabled platform that powers Intelligent Document Processing (IDP). The Cogniquest AI Platform helps businesses reduce the time employees spend on manual data collection and empowers them to focus on more critical tasks. To learn more about
The Unted States Patent and Trademark Office (USPTO) recently published new guidance on subject-matter eligibility as related to Artificial Intelligence (AI), opening a written comment window to respond with a deadline of September 16, 2024. The guidance was brought about by an October 2023 Executive Order on the “Safe, Secure, and Trustworthy Development and
America’s Seed Fund provides innovation funding for startups and small businesses across technology areas and markets. To discuss U.S. federal funding opportunities and eligibility, contact us at fedtrade@rothwellfigg.com
America’s Seed Fund is a startup innovation funding program of the U.S. National Science Foundation. Its purpose is to provide financial support to technology startups during the
It is fairly standard language in privacy policies: “This privacy policy may be amended or updated from time to time, so please check back regularly for updates.” It sends the message that the company can change its data practices and policies without ever notifying the end-user. It tells the end-user that the burden is on them
On Oct. 30, President Joe Biden issued an executive order on safe, secure and trustworthy artificial intelligence.[1]
The executive order provides a sprawling list of directives aimed at establishing standards for AI safety and security and protecting privacy.
While the executive order acknowledges the executive branch’s lack of authority for any lawmaking or rulemaking, AI
IP Innovation Management is the subject of a webinar sponsored by Medmarc Insurance Group. This event will be presented by James Hastings of Rothwell Figg. He is the editor of Healthcare Marketing Law.
IP Innovation Management is a process for:
the value inherent in intellectual assets creations.
Life sciences patents
Following its many warnings of impending enforcement action against entities providing Artificial Intelligence (“AI”) products, the FTC has officially launched an investigation into OpenAI[1]. The FTC initiates its investigation on the heels of the Center for AI and Digital Policy’s July 10, 2023 supplement to its March 30, 2023 complaint, which requests that